ClinicalTrials.gg
Active, not recruitingNCT03667651PEBBLESUpdated May 10, 2023

The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants

A Phase 3 interventional study of EpiCeram in Eczema, Asthma and Allergy;Food, sponsored by University of Melbourne. Active, not recruiting at 4 sites in Australia. Open to participants aged Up to 3 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-10.

Sponsored by University of Melbourne · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2018, registered Sep 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
760
Allocation
Randomized
Ages
Up to 3 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Eczema with a site in Australia — 4 open to participants now, 9 under way, 3 of them phase 3. Eczema · Australia.

Planned enrollment
8th of 40
760 · median 389
Started
2018
with 5 others
Phase 3
22 of 41
1 open now
Registered
11th of 41
by date

Among the 41 studies in Eczema with a site in Australia, this one is the 8th largest by planned enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2018, is one of 22 in phase 3, and was the 11th registered.

Eczema

507 studies on the registry are indexed under Eczema; 91 are open to participants now.

Browse Eczema studies →

Open to participants now

4 of the 41 studies in Eczema with a site in Australia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: Up to 3 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Eczema with a site in Australia, or all of them as a file.
02

Study summary

This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and food allergy in high risk infants.

A total of 760 participants with a first degree family history of allergic disease (asthma, eczema, allergic rhinitis or food allergy) will be recruited (380 each group) from maternity wards of three hospitals.

Read the detailed description

The primary objective of this study is to demonstrate that twice daily application of a ceramide dominant emollient reduces the risk of eczema and food allergy, when compared to standard skin management. Secondary objectives are to determine if twice daily application of a ceramide dominant emollient reduces the risk of infants developing allergic sensitisation (as measured by skin prick test); to determine if twice daily application of a ceramide dominant emollient improves infant skin barrier function; to determine the level of parental compliance with a program to build infant skin barrier function; to confirm that a ceramide dominant emollient does not cause adverse effects in infants; to determine the level of compliance required to demonstrate an improvement in infant skin barrier function and to determine if twice daily application of a ceramide dominant emollient influences infant skin microbial colonisation, or skin lipid profile.

This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and food allergy in high risk infants.

A total of 760 participants with a first degree family history of allergic disease (asthma, eczema, allergic rhinitis or food allergy) will be recruited (380 each group) from maternity wards of three hospitals.

Treatment will be from birth until six months, with a six week, six month and twelve month follow-up. An initial assessment will be performed at baseline which incorporates three surveys, a skin assessment, diary card (which is to be completed weekly and measures compliance), a breast milk sample, guthrie card and tape stripping. The six week and six month assessments entail a skin assessment, survey, compliance check, breast milk sample, tape stripping and guthrie card. Primary outcomes are assessed at the 12 month follow up where in addition to the aforementioned items, a saliva sample will also be taken and skin prick testing and food challenges will be performed when children have a positive SPT to one or more foods..

03

Conditions studied

  • Eczema
  • Asthma
  • Allergy;Food
04

Who can participate

Ages eligible
Up to 3 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Infants will be eligible for this study if their mother, father, or an older sibling has a self-reported history of at least one of the following conditions:

  • asthma,
  • eczema/atopic dermatitis,
  • hay fever/ allergic rhinitis or
  • food allergy

Exclusion Criteria: infants with any of the following will be excluded:

  • A parent who has a known to any of the ingredients of EpiCeram™ will be excluded, as it would be difficult for these parents to apply EpiCeram™ to their infant, and there is likely to be an increased risk of the infant reacting to the cream.
  • Multiple births (twins, triplets etc.) will be excluded, due to the difficulty in randomising individual twins and because of the clustering effect of multiple children from the same family which would reduce the effective sample size of the study.
  • Who are born premature (\<36 weeks) as the effect of the intervention may be different in premature infants.
  • Who have major birth or early life medical complications that require admission into a special care nursery, as it will be difficult for parents to comply with the study requirements.
  • Whose parents do not have sufficient English language skills to be able to answer questions.
  • Whose parents are not able to comply with all protocol required visits and procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
760 participants (estimated)

Study arms

  • Active comparator
    Twice daily use treatment with EpiCeram

    They will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for 6 months. The prophylactic use of EpiCeram™ is the intervention that is being tested for its effect on infant skin barrier function. We will instruct parents to apply approximately 6 grams of EpiCeram™ per application at two regular times each day, including after bathing the infant, or at the time they would normally bathe their child.

    Drug: EpiCeram

  • No intervention
    Standard skin care

    Parents are to follow standard skin care practices

Interventions

  • Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.

06

What researchers measure

Primary outcomes

  1. Presence of eczema

    as assessed using i) the UK working party criteria for eczema and/or ii) blinded investigator observed eczema.

    Time frame: 12 months of age.

  2. Confirmed diagnosis of food allergy at 12 months (52 weeks).

    This diagnosis is derived from a combination of allergic sensitisation, reaction history and food challenge. A skin prick test to six common allergens will be performed (egg white, cows' milk, peanut, dust mite, cat dander, and rye grass) along with a negative (saline) and a positive (histamine) control. Participants that are sensitised to certain foods (\>=1mm wheal) during the skin prick testing will be given a challenge to determine if they are allergic to those foods. This will be conducted at the MCRI Allergy Clinic under the supervision of a Doctor specifically trained in oral food challenges.

    Time frame: 12 months of age

Secondary outcomes

  1. Eczema severity

    assessed using the EASI score

    Time frame: 12 months of age

  2. Parent report of a community doctor diagnosis of eczema

    Time frame: 12 months of age

  3. infant skin barrier function

    As assessed by Trans-epidermal water loss (Vapometer)

    Time frame: At 6 weeks and 12 months of age

  4. Parental compliance with a program to build infant skin barrier function

    as assessed by parental completion of weekly diary cards and weighing of the tubes of study cream at each visit

    Time frame: At 6 weeks and 6 months of age.

  5. Adverse events

    as assessed by the documentation of any untoward medical occurrence in a participant enrolled into this study

    Time frame: From recruitment of infant until final study visit at 12 months of age.

  6. skin microbial colonisation, or skin lipid profile

    Assessed using skin swabs at baseline, 6 weeks and 12 months of age

    Time frame: At 6 weeks and 6 and 12 months of age

07

Study locations

4 sites
08

References and documents

Publications

  • Lowe A, Su J, Tang M, Lodge CJ, Matheson M, Allen KJ, Varigos G, Sasi A, Cranswick N, Hamilton S, Robertson CF, Hui J, Abramson M, O'Brien S, Dharmage S. PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy. BMJ Open. 2019 Mar 13;9(3):e024594. doi: 10.1136/bmjopen-2018-024594. PubMed 30867201 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2018 (actual). Primary completion is estimated for May 2027, 110 months after the start.

Of 71 phase 3 interventional studies under Eczema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 110 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2018
First posted
Sep 12, 2018
StartActual
Mar 6, 2018
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
May 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03667651
Lead sponsor
University of Melbourne
Responsible party
Adrian Lowe (Dr Adrian Lowe, University of Melbourne) — Principal investigator
First posted
Sep 12, 2018
Start date
Mar 6, 2018
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
May 10, 2023

Study contacts

Adrian J Lowe, Doctorate
principal investigator · University of Melbourne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EpiCeram

Start the discussion